Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

  • The Financial Times reports that an unknown American investor will be funneling $1B (€840M, £740M) to the UK, likely to support the country’s goal of building four £20B companies over the next decade.
  • Details of the UK government‘s plan to invest in biotech has underwhelmed many, as the projects covered in the report “are either already well known or vague and of questionable significance.”
  • Transgene has teamed up with BioInvent to work on an oncolytic virus encoding a CTLA4 checkpoint inhibiting antibody for solid tumors.

  • After a string of failures in allergy trials, Circassia scored a Phase IV win in chronic obstructive pulmonary disease (COPD).

  • Morphosys announced that the antibody it developed for Janssen has been approved for the treatment of moderate-to-severe plaque psoriasis in Canada.

Images via Kristel Segeren, kungverylucky, Parkol, Natalia Kuzmina / shutterstock.com

SaveSave

SaveSave

SaveSave

Previous post

French Biotech Misfires in Phase IIb Trial for Acute Myeloid Leukemia

Next post

A London Biotech Aims to Overtake the Dry Eye Syndrome Market

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.